Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Is ‘One to Watch’
FDA-approved LYMPHIR(TM) provides commercial-stage exposure to the oncology market. LYMPHIR(TM) generated $5.6 million in net revenue during the first six months of fiscal 2026 following its December 2025 commercial launch. Late-stage pipeline includes Mino-Lok(R), which met the primary and secondary endpoints of its pivotal Phase 3 trial. Diversified development portfolio targets critical-care indications with significant unmet medical needs. Halo-Lido could potentially become the first FDA-approved prescription product for the treatment of hemorrhoids in the United States. Stem cell platform provides an additional development opportunity targeting acute respiratory distress syndrome. Experienced leadership team has extensive pharmaceutical development, commercialization, sales, marketing and…
